Bambuterol: Effective in nocturnal asthma

Bambuterol was compared with placebo in 28 patients with nocturnal asthma in a randomized, double-blind cross-over study. All patients were symptomatic despite taking inhaled β 2 -agonists, inhaled corticosteroids (in 26 patients the median daily dose was 1500 μ g) and oral corticosteroids (in eight patients the median daily dose was 10 mg). Patients demonstrated ≥20% overnight fall in peak expiratory flow (PEF) for at least half of the 14-day run-in period. They then entered two treatment periods lasting 14 days when bambuterol 20 mg nocte and placebo were given in random order. Compared to placebo, bambuterol produced a 16% improvement in mean PEF on waking (271 l min −1 vs. 239 l min −1 P =0·0002) and a 10% improvement in evening PEF measured 24 h after drug intake (318 l min −1 vs. 296 l min −1 P =0·01). Bambuterol significantly reduced frequency of nocturnal awakening from 1·1 to 0·7 per night ( P =0·01) and nocturnal β 2 -agonist use from 2·7 to 2·1 puffs ( P =0·0004). Other nocturnal symptoms: cough, wheeze and dyspnoea were also significantly reduced during bambuterol treatment and patients quality of sleep was improved. The results indicate bambuterol (20 mg nocte) provides effective nocturnal bronchodilation with sustained effect for 24 h and may have a useful therapeutic role in the control of symptomatic nocturnal asthma.